Bullish
Autolus (Nasdaq: AUTL) grows AUCATZYL sales and cuts costs in Q1 2026
Autolus Therapeutics (AUTL) reported a strong increase in AUCATZYL net product revenue to $26.2 million in Q1 2026, up from $9.0 million a year prior,...